Dr. Tiwari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44035 Riverside Pkwy
Ste 300
Leesburg, VA 20176Phone+1 703-208-3155Fax+1 703-724-7503
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2014 - 2017
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2011 - 2014
Rural Medical College Pravara Institute of Medical SciencesClass of 2008
Certifications & Licensure
VA State Medical License 2021 - 2026
DC State Medical License 2017 - 2022
OH State Medical License 2010 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 40 citationsNeratinib, A Novel HER2-Targeted Tyrosine Kinase InhibitorShruti Rakesh Tiwari, Prasun J. Mishra, Jame Abraham
Clinical Breast Cancer. 2016-10-01 - 208 citationsInhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regenerationYongyou Zhang, Amar Desai, S. Yang, Ki Beom Bae, Monika I. Antczak
Science. 2015-06-12 - 3 citationsAdjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones
Nature Communications. 2024-03-27
Press Mentions
Greenwich LifeSciences Provides Year End UpdateDecember 29th, 2022- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
